Cyclacel Pharmaceuticals, Inc. (CYCC) Trades at $1.52 After Triangle; CENTERRA GOLD COMMON SHARES CANADA (CAGDF) Sellers Increased By 223.99% Their Shorts

April 17, 2018 - By Clifton Ray

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Logo

CENTERRA GOLD INC COMMON SHARES CANADA (OTCMKTS:CAGDF) had an increase of 223.99% in short interest. CAGDF’s SI was 425,400 shares in April as released by FINRA. Its up 223.99% from 131,300 shares previously. With 148,800 avg volume, 3 days are for CENTERRA GOLD INC COMMON SHARES CANADA (OTCMKTS:CAGDF)’s short sellers to cover CAGDF’s short positions. The SI to CENTERRA GOLD INC COMMON SHARES CANADA’s float is 0.22%. The stock increased 1.60% or $0.0988 during the last trading session, reaching $6.2588. About 5,714 shares traded. Centerra Gold Inc. (OTCMKTS:CAGDF) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Cyclacel Pharmaceuticals, Inc. (CYCC) formed triangle with $1.61 target or 6.00% above today’s $1.52 share price. Cyclacel Pharmaceuticals, Inc. (CYCC) has $18.24M valuation. The stock decreased 2.25% or $0.03 during the last trading session, reaching $1.52. About 121,831 shares traded. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has declined 63.19% since April 17, 2017 and is downtrending. It has underperformed by 74.74% the S&P500.

Analysts await Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) to report earnings on May, 10. They expect $-0.13 EPS, up 65.79% or $0.25 from last year’s $-0.38 per share.

Centerra Gold Inc., a gold mining and exploration company, engages in the acquisition, exploration, development, and operation of gold properties in Asia, North America, and internationally. The company has market cap of $1.75 billion. The Company’s principal projects include Kumtor gold mine located in the Kyrgyz Republic; and the Mount Milligan mine located in Canada. It has a 8.74 P/E ratio. The firm also holds 100% interests in the Altan Tsagaan Ovoo exploration property located in Mongolia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: